NextCure, Inc. (NXTC)
Develops experimental cancer drugs that unlock immune cells to fight tumors.
$5.42+0.06%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+10.8%
The outlook
NextCure is trading near the bottom of its 52-week range, with analyst coverage leaning strongly bullish and an average price target about 269% above the current level. The stock's recent price action shows mixed momentum relative to its moving averages. Overall sentiment leans bullish, though conviction from the three-analyst group is moderate.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 3 analysts
Price trendMixed vs its moving averages
52-week range27% of the way from its 52-week low to high
Price targetAvg target +269% vs current price
Analyst price target
~12-month · 3 analysts$20.00average target+269.0% vs now
Now $5.42
Low $15.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$19.6M
52-wk high
$15.74
52-wk low
$1.55
50-day avg
$4.18
200-day avg
$9.53
Trailing P/E
—